Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Radius Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteopor...
Brand Name : Binosto
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Radius Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Abiogen Pharma S.p.A
Deal Size : Undisclosed
Deal Type : Acquisition
Abiogen Pharma Completes the Acquisition of EffRx Pharmaceuticals
Details : Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of os...
Brand Name : Binosto
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 29, 2023
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Abiogen Pharma S.p.A
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?